The Refractory DermatoMyositis Index (ReDMI): a clinical tool to predict refractory disease in patients with dermatomyositis
After external validation, the ReDMI may be a useful clinical tool to timely detect DM patients at risk of developing refractory disease who may be candidates to receive an early more aggressive therapy.
Authors
- Martha E. Baños-Laredo
- María Lilia Domínguez-López
- Carlos A. Núñez‐Álvarez (ORCID: https://orcid.org/0000-0002-5051-0389)
- Jennifer Balderas-Miranda (ORCID: https://orcid.org/0000-0002-2364-7697)
- María José Ostos-Prado (ORCID: https://orcid.org/0009-0000-9347-8705)
- Yatzil Reyna-Juárez (ORCID: https://orcid.org/0000-0002-9558-893X)
- Agustín Hernández-López (ORCID: https://orcid.org/0000-0002-4889-546X)
- Karina Santana de Anda
- Andrés López Gaytán
- Nancy Raquel Mejía-Domínguez
- Diana Gómez-Martín
- Beatriz Alcalá-Carmona
- Jiram Torres-Ruiz
Institutions
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- Instituto Politécnico Nacional (MX)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2025-06-18
- DOI
- https://doi.org/10.55563/clinexprheumatol/k77xaj
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 0.00